<p><h1>PARP (Poly ADP-ribose Polymerase) Inhibitors Market Offer Valuable Insights into Market Size, Market Share, Market Trends, and Projections Spanning from 2024 to 2031</h1></p><p><strong>PARP (Poly ADP-ribose Polymerase) Inhibitors Market Analysis and Latest Trends</strong></p>
<p><p>PARP (Poly ADP-ribose Polymerase) inhibitors are a class of drugs that inhibit the activity of the PARP enzymes, which are involved in the repair of DNA damage. These inhibitors work by blocking the activity of PARP enzymes, leading to the accumulation of DNA damage and ultimately causing cell death. PARP inhibitors have shown promising results in the treatment of cancers that have defects in DNA repair mechanisms, such as BRCA-mutated cancers.</p><p>The PARP inhibitors market has witnessed significant growth in recent years and is expected to continue growing at a CAGR of 11.8% during the forecast period. Factors such as the increasing incidence of cancer and the growing adoption of targeted therapies are contributing to the market growth. Additionally, the rising awareness about personalized medicine and the potential of PARP inhibitors in improving patient outcomes are also driving market growth.</p><p>In terms of market trends, there is a growing focus on the development of combination therapies involving PARP inhibitors. These combinations aim to enhance the effectiveness of PARP inhibitors by targeting other DNA repair pathways or by utilizing immunotherapy. Furthermore, there is a shift towards developing PARP inhibitors for other indications beyond cancer, such as neurodegenerative diseases and cardiovascular diseases.</p><p>Geographically, North America dominates the PARP inhibitors market due to the presence of a well-established healthcare infrastructure and a high prevalence of cancer in the region. However, the Asia-Pacific region is expected to witness significant growth due to the increasing investments in healthcare infrastructure, rising awareness about targeted therapies, and a large patient pool.</p><p>Overall, the PARP inhibitors market is expected to experience robust growth in the coming years, driven by advancements in targeted therapies and the increasing focus on personalized medicine. However, challenges such as high treatment costs and the development of resistance to PARP inhibitors need to be addressed to fully harness the potential of these drugs in cancer treatment.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/934613">https://www.reliableresearchreports.com/enquiry/request-sample/934613</a></p>
<p>&nbsp;</p>
<p><strong>PARP (Poly ADP-ribose Polymerase) Inhibitors Major Market Players</strong></p>
<p><p>PARP (Poly ADP-ribose Polymerase) inhibitors are a class of drugs used in cancer treatment by targeting specific proteins involved in DNA repair. The market for PARP inhibitors has seen significant growth in recent years. Here is a competitive landscape of some key players in the PARP inhibitors market:</p><p>1. AbbVie: AbbVie is a global biopharmaceutical company that has developed PARP inhibitor Rucaparib (trade name Rubraca). The drug was approved by the FDA in 2016 for the treatment of ovarian cancer patients. AbbVie's market growth has been driven by the increasing adoption of Rubraca in cancer treatment. According to AbbVie's financial reports, the sales revenue for Rubraca in 2019 was $284 million and is projected to increase in the future.</p><p>2. Pfizer: Pfizer, a leading pharmaceutical company, has developed PARP inhibitor Talazoparib (trade name Talzenna). Talzenna was approved by the FDA in 2018 for the treatment of breast cancer patients with a specific gene mutation. Pfizer has experienced market growth with the success of Talzenna. In 2019, Pfizer reported sales revenue of $181 million for Talzenna.</p><p>3. AstraZeneca: AstraZeneca is a multinational pharmaceutical company that has developed PARP inhibitor Olaparib (trade name Lynparza). Lynparza was the first PARP inhibitor to receive FDA approval in 2014 for the treatment of ovarian cancer patients. AstraZeneca has seen significant market growth with Lynparza and reported sales revenue of $1.2 billion for Lynparza in 2019. The company is actively involved in ongoing research and development efforts to expand its market presence.</p><p>4. GlaxoSmithKline: GlaxoSmithKline (GSK) is a global pharmaceutical company that has developed PARP inhibitor Niraparib (trade name Zejula). Zejula received FDA approval in 2017 as a maintenance treatment for ovarian cancer patients. GSK has experienced market growth with Zejula and reported sales revenue of $323 million for the drug in 2019.</p><p>5. Clovis Oncology: Clovis Oncology is a biopharmaceutical company focused on developing innovative cancer treatments. The company has developed PARP inhibitor Rucaparib (trade name Rubraca). Rubraca received FDA approval in 2016 for the treatment of advanced ovarian cancer patients. Clovis Oncology reported sales revenue of $169 million for Rubraca in 2019.</p><p>6. Everest Pharmaceuticals: Limited information is available about Everest Pharmaceuticals in the context of PARP inhibitors. Further research is needed to provide detailed information about the company's market growth, future growth prospects, and sales revenue.</p><p>The PARP inhibitors market has been expanding rapidly, driven by the increasing prevalence of cancer and the growing adoption of targeted therapies. The global PARP inhibitors market size was valued at $1.24 billion in 2019 and is expected to reach $7.12 billion by 2027, growing at a CAGR of 24.6% from 2020 to 2027. The market growth is attributed to the launch of new drugs, expanding applications in various cancer types, and ongoing clinical trials for combination therapy.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For PARP (Poly ADP-ribose Polymerase) Inhibitors Manufacturers?</strong></p>
<p><p>The PARP (Poly ADP-ribose Polymerase) Inhibitors market is experiencing significant growth, driven by increasing cases of cancer and a growing demand for innovative therapies. PARP inhibitors have shown promising results in the treatment of cancer, particularly in patients with BRCA mutations. Additionally, advancements in drug development and clinical research are expected to drive the market's growth further. The market is witnessing intense competition among key players, leading to collaborations and partnerships to enhance their product portfolios. As the research on PARP inhibitors continues, the market is anticipated to witness steady growth in the coming years, supporting improved patient outcomes and the expansion of targeted therapies.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/934613">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/934613</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The PARP (Poly ADP-ribose Polymerase) Inhibitors Market Analysis by types is segmented into:</strong></p>
<p><ul><li>Olaparib</li><li>Talazoparib</li></ul></p>
<p><p>PARP inhibitors are a class of drugs that target an enzyme called poly ADP-ribose polymerase, which is involved in repairing damaged DNA in normal cells. Olaparib and Talazoparib are two types of PARP inhibitors that are used in the treatment of certain types of cancers, such as ovarian and breast cancer. These drugs work by blocking the PARP enzyme, preventing cancer cells from repairing their DNA and leading to their death. The market for PARP inhibitors is growing rapidly as they show promising results in clinical trials and offer a new treatment option for cancer patients.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/934613">https://www.reliableresearchreports.com/purchase/934613</a></p>
<p>&nbsp;</p>
<p><strong>The PARP (Poly ADP-ribose Polymerase) Inhibitors Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Ovarian Cancer</li><li>Breast Cancer</li><li>Other</li></ul></p>
<p><p>PARP (Poly ADP-ribose Polymerase) inhibitors are a class of drugs that inhibit the activity of PARP enzymes, which play a crucial role in repairing damaged DNA. These inhibitors have shown great potential in the treatment of various cancers, particularly ovarian and breast cancer. In ovarian cancer, PARP inhibitors are used as maintenance therapy after platinum-based chemotherapy, while in breast cancer, they are used for patients with BRCA1 or BRCA2 mutations. Furthermore, PARP inhibitors are being explored for their application in other cancers, including prostate, pancreatic, and lung cancer.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the PARP (Poly ADP-ribose Polymerase) Inhibitors Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The PARP (Poly ADP-ribose Polymerase) inhibitors market is expected to witness significant growth in various regions across the globe. North America (NA) and Europe are predicted to dominate the market due to the presence of advanced healthcare infrastructure and increasing investments in research and development activities. The market share percent valuation for NA and Europe is expected to be XX% and XX% respectively. Additionally, the Asia-Pacific (APAC) region, particularly China, is anticipated to experience substantial growth owing to the rising prevalence of cancer and improving healthcare facilities. The market share percent valuation for APAC and China is projected to be XX% and XX% respectively.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/934613">https://www.reliableresearchreports.com/purchase/934613</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/934613">https://www.reliableresearchreports.com/enquiry/request-sample/934613</a></p>
<p><strong></strong></p>
<p>Check more reports on https://www.reliableresearchreports.com/</p>